Coenzyme A contained in mothers' milk is associated with the potential to induce atopic dermatitis.
T(h)2 adjuvant activity can be qualitatively and quantitatively evaluated using a mixed lymphocyte reaction and by changes in the intracellular cyclic adenosine 3',5'-monophosphate concentration, using human dendritic cells in vitro. The current study shows that mothers, whose children (n = 55) developed atopic dermatitis (AD) within 6 months after birth, often demonstrate a higher T(h)2 adjuvant activity in their milk, in comparison to those whose children did not develop such symptoms. Such an activity was recovered in a liquid phase of mothers' milk and was eluted as a single fraction by reversed-phase HPLC. Further analysis of this fraction by mass spectrometry showed that signals originating from a factor with a molecular weight of 767.53 are observed, exclusively in milk with a high T(h)2 adjuvant activity. The mass is exactly that of Coenzyme A (CoA), and indeed, a low concentration of CoA exhibited T(h)2 adjuvant activity both in vitro and in vivo. Moreover, mesenteric lymph node non-T cells obtained from mice that were orally treated with CoA led allogeneic naive CD4(+) T cells to differentiate into T(h)2. Furthermore, the oral administration of CoA induced rough skin, hyperplasia of the epidermis, hypergranulosis in the spinous layer and the thickening of the stratum in mice. These data collectively indicate that some of the patients with AD were exposed to mothers' milk carrying high T(h)2 adjuvant activity right after birth, which may be attributable to presence of CoA contained in the milk.
Department of Allergy and Immunology, Faculty of Medicine, Moroyama, Saitama 350-0495, Japan.
Takehiro
T
Higashi
Naoki
N
Shimojo
Shuichi
S
Suzuki
Mayuko
M
Nakaya
Rie
R
Takagi
Kumiko
K
Hashimoto
Kazuyuki
K
Nakagome
Koichiro
K
Nakamura
Yoichi
Y
Kohno
Sho
S
Matsushita
D000818:Animals; D001942:Breast Feeding / Q000009:adverse effects; D002454:Cell Differentiation; D002460:Cell Line; D003065:Coenzyme A / Q000032:analysis / Q000276:immunology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D003876:Dermatitis, Atopic / Q000276:immunology*; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007231:Infant, Newborn; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008895:Milk, Human / Q000201:enzymology / Q000276:immunology*; D011446:Prospective Studies; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D058408:Th1-Th2 Balance; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
D016207:Cytokines; D003065:Coenzyme A